Why Pharmacogenomics Is Becoming Standard of Care

For most of modern medicine, prescribing has involved an educated guess. A provider chooses a medication that works for most people, starts at a typical dose, and adjusts based on how the patient responds. For many patients, that works fine. For many others — particularly older adults on multiple medications — it means weeks or months of trial and error, side effects, and the quiet erosion of trust that comes with feeling like a test case.

Pharmacogenomics (PGX) changes the starting point. By testing how an individual's genetics affect the way they metabolize and respond to specific drugs, a provider can prescribe with far more confidence from the very first visit. What was once specialty knowledge confined to oncology and psychiatry is now moving steadily into everyday primary care, where the volume of prescribing — and the volume of preventable problems — is highest.

The shift matters most for the people we think about most: seniors managing eight or ten prescriptions, where a single poorly matched medication can cascade into falls, confusion, or a hospital stay. PGX testing lets a provider see, before writing the prescription, which medications are likely to help and which are likely to cause trouble. It turns a guess into an informed decision.

Becoming standard of care, though, is not only a clinical question — it is an operational one. Practices need clear workflows, provider education, patient-friendly ways to explain the results, and a reimbursement model that makes the program sustainable. That is where we help. The science is ready. The work now is making it practical, so that the right medication for the right patient becomes the rule rather than the exception.

← Back to Insights